Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti
16/3/2021
0:00
16:48
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.
Otros episodios de "MedEdTalks - Gastroenterology"
No te pierdas ningún episodio de “MedEdTalks - Gastroenterology”. Síguelo en la aplicación gratuita de GetPodcast.